Abstract

Purpose/Objective: Neoadjuvant in situ cytotoxic gene therapy can potentially trigger a systemic immune response, which could impact occult micro-metastatic disease. We are currently conducting three clinical trials using in situ adenoviral vector mediated Herpes Simplex Virus-thymidine kinese (HSV-tk) gene plus ganciclovir (GCV) therapy. This study evaluates the systemic T-cell response following gene therapy in each trial.

Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.